GLP1RA DM ASCVD

active
URL
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.680
Version
20240206
PublisherOptum StewardDate2024-02-06T01:09:28-05:00Description

Excluded oral form of semaglutide (only Rybelsus)

Purpose

(Clinical Focus: Medications containing GLP-RAs that have evidence for benefit in ASCVD (that is, reduction in MACE - major adverse cardiac events) per the ADA Standards of Care in Diabetes 2023),(Data Element Scope: DRUG_CLASS_MEMBERS: PHARMACOLOGIC:),(Inclusion Criteria: RxCUIs for medications containing one of the following ingredients: * dulaglutide * liraglutide * semaglutide (ONLY subcutaneous form)),(Exclusion Criteria: Excluded oral form of semaglutide)

Expansion
<<>>>
CodeDisplaySystem
1858994http://www.nlm.nih.gov/research/umls/rxnorm
1598267http://www.nlm.nih.gov/research/umls/rxnorm
2619154http://www.nlm.nih.gov/research/umls/rxnorm
1551304http://www.nlm.nih.gov/research/umls/rxnorm
847913http://www.nlm.nih.gov/research/umls/rxnorm
897126http://www.nlm.nih.gov/research/umls/rxnorm
1991317http://www.nlm.nih.gov/research/umls/rxnorm
1551291http://www.nlm.nih.gov/research/umls/rxnorm
2554102http://www.nlm.nih.gov/research/umls/rxnorm
847917http://www.nlm.nih.gov/research/umls/rxnorm
2553601http://www.nlm.nih.gov/research/umls/rxnorm
2619152http://www.nlm.nih.gov/research/umls/rxnorm
2553500http://www.nlm.nih.gov/research/umls/rxnorm
2553602http://www.nlm.nih.gov/research/umls/rxnorm
1551292http://www.nlm.nih.gov/research/umls/rxnorm
2395779http://www.nlm.nih.gov/research/umls/rxnorm
1860171http://www.nlm.nih.gov/research/umls/rxnorm
1649586http://www.nlm.nih.gov/research/umls/rxnorm
2599361http://www.nlm.nih.gov/research/umls/rxnorm
1860168http://www.nlm.nih.gov/research/umls/rxnorm